GlassScriptPhysician profile
Cathal P Grant
NPI 1255384145
$414,460.90
in general payments reported to CMS, 2019-2025
39 companies · $38K in 2025
The $38K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $28K · 2021: $60K · 2022: $84K · 2023: $88K · 2024: $78K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Honoraria: $46K · Consulting Fee: $20K · Food and Beverage: $19K · Travel and Lodging: $19K · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,430.00 |
| Honoraria | $45,850.00 |
| Consulting Fee | $19,590.00 |
| Food and Beverage | $19,407.20 |
| Travel and Lodging | $19,080.91 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101,079.77 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $73,893.93 | 2021-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $53,171.29 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Allergan, INC. | $52,955.95 | 2019-2020 | |
| Axsome Therapeutics, INC. | $31,962.05 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30,962.05 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $24,636.83 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $14,921.83 | 2020-2025 | Lybalvi, Aristada, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $5,774.31 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $5,199.24 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Validus Pharmaceuticals LLC | $3,870.87 | 2019-2025 | Equetro, Equetro, Raldesy |
| Teva Pharmaceuticals USA, INC. | $3,085.13 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,544.73 | 2019-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $1,506.13 | 2021-2025 | Azstarys, Azstarys |
| Sunovion Pharmaceuticals INC. | $1,415.99 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathal Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.